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a  b  s  t  r  a  c  t
The  current,  and  welcome,  focus  on standardization  of techniques  and  transparency  of  reporting  in the
biomedical,  peer-reviewed  literature  is  commendable.  However,  that focus  has  been  intermittent  as  well
as lacklustre  and  so  failed  to  tackle  the alarming  lack  of  reliability  and  reproducibly  of  biomedical  research.
Authors  have  access  to  numerous  recommendations,  ranging  from  simple  standards  dealing  with  tech-icroarrays
ext generation sequencing
nical issues  to those  regulating  clinical  trials,  suggesting  that improved  reporting  guidelines  are  not  the
solution.  The  elemental  solution  is  for editors  to require  meticulous  implementation  of  their  journals’
instructions  for  authors  and  reviewers  and  stipulate  that no paper  is  published  without  a  transparent,
complete  and  accurate  materials  and  methods  section.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CCThe treatment of some scientiﬁc topics, particularly in biomed-
cal research, is very much like that afforded to the catwalk fashion
ndustry; something becomes hyped, everyone talks about it and
ventually the popular press picks up the topic and generally dis-
ort its conclusions, only for the band wagon to move on to the next
ot topic. Tellingly, this excitement is usually misplaced and serves
ore to publicize the particular authors, institutions and journals
han it does to contribute to any advancement in scientiﬁc knowl-
dge or translational beneﬁt. In contrast, vast amounts of scientiﬁc
ata are published without eliciting any interest whatsoever, leav-
ng the authors to cite their own papers in the hope that their work
ill, one day, become the hyped fashion. Regardless, the results and
onclusions from much, if not most, of the publications of biomed-
cal research are questionable: the majority are not reproducible
1–3] and so do not satisfy one of the fundamental requirements of
cientiﬁc research. There are a number of reasons why  published
esults cannot be reproduced:
. The original research was carried out incorrectly, for example
without sufﬁcient regard for sample selection, template quality
or inappropriate data analysis.
. The attempts to replicate results are ﬂawed because the infor-
mation provided in the publication is not sufﬁciently detailed
and explicit.
. The replicating laboratories do not have sufﬁcient understanding
of the uncertainty associated with their experiments. For exam-
ple, the high precision of methods like digital PCR can generate
different results, but a more focused look at reproducibility may
show they are all describing different parts of a data distribu-
tion, which, once understood, would allow a deﬁnition of what
can actually be measured.
ttp://dx.doi.org/10.1016/j.bdq.2015.11.002
214-7535/© 2015 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Any of these explanations is objectionable and results in billions
of dollars being wasted every year [4]. This message is, of course, not
new [5] and over the last twenty years or so there have been numer-
ous, often high proﬁle, publications lamenting this state of affairs
and proposing solutions, most recently summarized in a review
article published in this journal [6].
Why  is there this apparent indifference to publication quality?
Is it because detailed scrutiny of the reliability, standardization,
reproducibility and transparency of methods is perceived as com-
paratively mundane and unexciting? Is the current peer review
process inadequate to provide a reliable analysis of all techniques?
In theory, there is no disagreement about the importance of the
methods section of a scientiﬁc manuscript [7] or that it requires a
clear, accurate [8] and, crucially, adequate description of how an
experiment was carried out. In theory, it is also accepted that the
aim of a methods section is to provide the information required to
assess the validity of a study and hence be sufﬁciently detailed so
that competent readers with access to the necessary experiment
components and data can reproduce the results.
Certainly, despite the wealth of evidence that published meth-
ods are wholly deﬁcient, there has never been any determined,
consistent and coherent effort to address these issues and deal with
their consequences. Therefore a welcome, recent effort involves
the publication of a report based on the proceedings of a sympo-
sium held earlier this year, aimed at exploring the challenges and
chances for improving the reliability and reproducibility and of
biomedical research in the UK (http://www.acmedsci.ac.uk/policy/
policy-projects/reproducibility-and-reliability-of-biomedical-
research/). However, a close reading of the report suggests that
it simply summarizes all of the ﬁndings and opinions that are
already published and suggests the same solutions that have
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een ignored until now. These include “top-down measures from
ournals, funders and research organisations” that aim to improve
he quality of training and institute a research culture and career
tructure that reduces the emphasis on novelty and publication,
s well as “bottom-up ones from individual researchers and lab-
ratories” that address issues of poor study design and statistical
ractices, inadequate reporting of methods, and problems with
uality control. What is lacking is a decisive, headline-grabbing
all to action.
Some of the suggestions also imply that the authors of this
eport appear not to be overly familiar with existing, long standing
fforts to standardize protocols and improve transparency. For
xample, in a section with the heading “strategies to improve
esearch practice and the reproducibility of biomedical research”
ontains the suggestion that establishing standards could address
ome of the issues associated with reproducibility and points
o the Minimum Information About a Microarray Experiment
MIAME) guidelines [9] as the exemplary standard. In fact, there
re numerous “Minimum Information” standards projects fol-
owing on from that paper, most of which have been registered
ith the Minimum Information for Biological and Biomedi-
al Investigations initiative (http://www.dcc.ac.uk/resources/
etadata-standards/mibbi-minimum-information-biological-
nd-biomedical-investigations), where they are collected and
urated and can be accessed through a searchable portal of
nter-related data standards, databases, and https://biosharing.
rg/standards. Complementary information is also available
rom the US National Library of Medicine website, which lists
he organizations that provide advice and guidelines for report-
ng research methods and ﬁndings (https://www.nlm.nih.gov/
ervices/research report guide.html). Medical research studies, in
articular, are well served with reporting guidelines, for example
y the EQUATOR Network, which aims to improve the reliability
nd value of the medical research literature by promoting trans-
arent and accurate reporting (http://www.equator-network.org).
here are reporting guidelines for many different study designs
uch as CONSORT (www.consort-statement.org) for randomized
rials, STARD for studies of diagnostic accuracy (www.stard-
tatement.org/) and SPIRIT for study protocols (http://www.spirit-
tatement.org).
If it were simply a matter of developing standards, then the state
f the peer-reviewed literature would not be as scandalous as it is.
he real problem stems from the lack of application of those stan-
ards. This is most easily demonstrated by looking at, arguably,
he most widely used molecular techniques, real-time PCR (qPCR)
nd reverse transcription (RT)-qPCR. These methods have found
upporting roles as part of a huge number of publications in every
rea of the life sciences, clinical diagnostics, biotechnology, foren-
ics and agriculture. qPCR-based assays are usually described as
imple, accurate and reliable. This is true, but only if certain tech-
ical and analytical criteria are met. It is especially important to
mphasize that the accuracy of results is critically dependent on
he choice of calibration, whether this be a control sample or a cal-
bration curve. This method is easily abused and one particularly
gregious example is provided by its use to detect measles virus in
he intestine of autistic children. Numerous, independent replica-
ion attempts, including those carried out by the original authors,
ailed to reproduce the original data and an analysis of the raw
ata, carried out as part of the US autism omnibus trial in Wash-
ngton DC, revealed that the conclusions were based on fallacious
esults obtained by a combination of sample contamination with
NA, incorrect analysis procedures and poor experimental meth-
ds [10,11]. A paper publishing these data remains to be retracted
3 years after publication. While this delay is typical, it is totally
nacceptable and results in an underestimation of the role of fraud
n the ongoing retraction epidemic [12,13].d Quantiﬁcation 7 (2016) A1–A5
A typical problem associated with qPCR assay variability is illus-
trated in Fig. 1, which demonstrates that qPCR assays can behave
signiﬁcantly different under different experimental conditions. As
the data demonstrate, at the higher target DNA  concentration both
assays generate reliable data. However, at the lower concentration,
results are reliable from only one of the assays (A), with the Cq of
5.98 ± 0.21 between two different target DNA concentrations being
in line with the expected value for the dilution factor. In contrast,
the results of the other assay (B) are much more variable, (Cq of
8.29 ± 1.65) and also do not accurately reﬂect the dilution factor.
The report by Dr. Andreas Nitsche in this issue shows that some
assays are particularly sensitive to variability in different buffers
and even different batches of same buffer. If assay behavior is not
thoroughly assessed such that experimental conditions are simu-
lated, prior to carrying out real-life tests, this can lead to false results
and confound any potential conclusions.
The MIQE guidelines, published in 2009 [14], are among the
most cited molecular recommendations (nearly 4000 citations vs
around 3500 for the MIAME  guidelines published in 2001). They
describe the minimum information necessary for evaluating qPCR
experiments and include a checklist comprising nine sections to
help guide the author to the full disclosure of all reagents, assay
sequences and analysis methods and so help to minimise this kind
of variability or potential inaccuracy. The guidelines suggest appro-
priate parameters for qPCR assay design and reporting, and have
become widely accepted by both the research community and,
especially, the companies producing and selling qPCR reagents
and instrumentation. Implementation of these guidelines has been
demonstrated to result in the publication of more complete and
transparent papers, although the majority of qPCR-based papers
continue to provide inadequate information on experimental detail
[15].
There can be no doubt that there are a vast number of unreli-
able and incorrect results published that have been generated by
qPCR, a relatively simple technique. This begs the obvious question
of how reliable the results are that have been obtained using signiﬁ-
cantly more demanding methods. An example is digital PCR (dPCR),
which involves the dilution and partitioning of target molecules
into large numbers of separate reaction chambers so that each
contains either one or no copies of the sequence of interest [16].
A comparison of the number of partitions in which the target is
detected vs those in which it is not, allows quantitative analysis
without the need for a calibration curve. Hence data analysis can
be not just more precise, but also more straightforward than with
qPCR. However, there are additional parameters that any reader
of a publication using this technology needs to be aware of, most
obviously the mean number of target copies per partition, the num-
ber of partitions, individual partition volumes and the total volume
of the partitions measured. Hence the necessary requirement for
the publication of the digital PCR MIQE guidelines, which address
known requirements for dPCR that were identiﬁed during the early
stage of its development and commercial implementation [17].
Expression microarrays and next generation sequencing incor-
porate an additional layer of complexity. Whilst the parameters
required to ensure reliable qPCR and dPCR results are reasonably
few, those required to assess the validity of expression microar-
rays or RNA sequencing are signiﬁcantly more complex. There
have been several papers investigating the effects of technical and
bioinformatics variability of RNA-seq results [18–21] and stan-
dards for RNA sequencing [22,23] (http://www.modencode.org/
publications/docs/index.shtml) as well as Chromatin immunopre-
cipitation and high-throughput DNA sequencing (ChIP-seq) [24]
are being developed, but again there is no decisive push for their
universal acceptance.
There is a correlation between the number of retractions and
the impact factor of a journal [12]. While this could be due to the
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Fig. 1. Comparison of a dualplex qPCR assay targeting Candida dublinensis or Candida glabrata. (1) A PCRmax Eco (http://www.pcrmax.com) was used to amplify 100 pg of C.
glabrata (A) and C. dublinensis (B) and DNA. Four replicate reactions were run of 5 l each using Agilents’s Brilliant III qPCR mastermix, with PCR amplicons detected using

























Nverage Cqs of 25.16 ± 0.19 and 25.44 ± 0.19 for C. glabrata and C. dublinensis, respec
.5  pg of each of the fungal DNAs. (4) Plot of the two  assays recording average Cqs of
reater subsequent scrutiny afforded results published in a high
mpact factor journal, it surely is worth noting that despite the
xclusivity of such publications and the pre-publication scrutiny
hey endure, such publications occur at all. It is also striking that
here is an inverse correlation between MIQE compliance and
mpact factor [25] demonstrating the lack of adequate reporting
f method for, at least, this single technique. The link between
dequate reporting of methods and lack of reproducibility has
ecome more widely accepted, and the publishers of Nature have
eleased a coordinated set of editorial statements that admitted
hat the Nature publishing group had failed to “exert sufﬁcient
crutiny over the results that they publish” and introduced a
hecklist to encourage the publication of more detailed experi-
ental methods [26–35]. However, these laudable aims have not
een followed up by meaningful action and a recent analysis of
ature-published articles suggests that none of the parameters
eemed to be essential for reliable RT-qPCR reporting are actu-
lly being reported [6]. We  have repeated the analysis with six
apers [36–41] published in 2015 by the Nature group and found
hat authors and reviewers are still not heeding their own  jour-
als’ publication guidelines. The following description of the RNA
xtraction, reverse transcription and RT-qPCR steps published in
ature genetics is typical: “RNA was extracted with the Nucle- (Mean ± SD). (3) Conditions as described for 1, except that the replicates contained
 ± 0.09 and 33.73 ± 1.64 for C. glabrata and C. dublinensis, respectively (Mean ± SD).
ospin II kit (Macherey-Nagel) and reverse-transcribed using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). PCRs were performed either using TaqMan assays with
qRT-PCR Mastermix Plus without UNG (Eurogentec) or using SYBR
green (Applied Biosystems). Oligonucleotides were purchased from
MWG  Euroﬁns Genomics (supplementary data). Reactions were
run on an ABI/PRISM 7500 instrument and analyzed using the
7500 system SDS software (Applied Biosystems)” [39]. At least the
authors published the primer sequences, although access to this
information reveals that, once again, they used a single unvalidated
reference gene.
What about other high impact factor journals? We  have ana-
lyzed ten papers that include RT-qPCR-based results published in
2015 in Cell and its associated journals, to see whether the edi-
tors of these high impact factor journals pay any more attention
to transparency of reporting (Fig. 2). Not one paper reports any
experimental detail, all use inappropriate normalization proce-
dures yet all of them include extensive supplementary information.
Since there is no limit on the pages published with these online
supplements, there is no excuse for omitting these basic criteria.
Furthermore, all but one use single, unvalidated reference genes
for data normalization, which is similar to what was found in a
previous large scale study conﬁned to colorectal cancer biomarker
A4 Perspective / Biomolecular Detection and Quantiﬁcation 7 (2016) A1–A5
Fig. 2. Analysis of ten papers published in Cell [45,46], Cell Stem Cell [47,48], Cancer Cell [49–51] and Molecular Cell [52–54] between June and November 2015. Materials
and  methods and supplementary sections were screened for information on seven key parameters required to assess the technical validity of RT-qPCR assays, detailed on


































ihe  x-axis. The number of papers reporting any one of these parameters are shown
ublished with each of the ten papers. The one paper using two reference genes (R
tability of these targets, either alone or in combination.
ublications [42]. This practice was demonstrated to be unreliable
 long time ago for the kind of small fold-changes these papers
re reporting and should have been abandoned by now [43,44].
ence the validity of the reported data are, at the very least, open
o doubt. The results of this analysis reinforce the shocking conclu-
ion that the editors of these high impact factor journals have still
ot received and acted upon the requirement for reporting of qPCR
nd RT-qPCR experimental procedures.
So what is the solution? Obviously, since the problem is multi-
actorial involving, researchers, grant awarding bodies and journal
ublishers, no single party is solely responsible, and therefore no
ingle solution will sufﬁce [55]. However, an essential step is that
ournal editors enforce their own, published standards and insist
hat reviewers scrutinize carefully the materials and methods sec-
ions of submitted manuscripts. Whilst no single reviewer has the
xpertise to assess the nuances of every single technique used,
dherence to guidelines helps with that evaluation and every jour-
al should retain a pool of technical reviewers who would evaluate
ot just the technical acceptability but, equally important, the
ransparency of reporting. As the data in Fig. 2 show, most papers
rovide no information at all about experimental procedures relat-
ng to RT-qPCR. Of course, there is also an onus on the readers of
 paper to be more critical of published research ﬁndings and use
heir common sense to evaluate the likelihood of a result being real
r not. In this age of blogs and public comments, it would be a sim-
le procedure to email the editor handling any particular paper so
hat any publication could be open to reader comments regarding
anuscripts on the website. This would allow the peer reviewed
iterature to be updated and those remaining that fail to be suf-
ciently transparent or where results do not support conclusions
ould be called out as questionable, thus gradually reducing their
mpact and removing them from the ongoing citations. The good
ntentions have been published, now it is time for editors to act.
We would offer some practical solutions for discussion:e left hand y-axis. The right hand y-axis shows the number of supplemental pages
s both one and two RG in different experiments without explicit validation of the
1. Journals
a. Maintain a checklist of reporting requirements for each tech-
nique (such as provided by MIQE guidelines) and reject at
submission any manuscript without associated standards
checklists completed.
b. Manuscripts should be submitted with data from replicate
experiments, even if these are not to be published in the body
of the paper so that the reviewer sees a demonstration that
the experiment is reproducible in the authors’ hands.
c. Insist that papers are reviewed by technical experts, such that
all techniques reported in the paper are reviewed, using more
than the traditional two reviewers if necessary.
d. Publish reader comments, queries and challenges to
manuscripts in an open forum.
e. Publishers could pay for group of independent monitors that
carry out an annual survey of peer reviewed publications,
grouped into various specialties, and publish annual league
tables of compliance with sector-speciﬁc guidelines.
2. Reviewers
a. Call to account papers without sufﬁcient detail for an accurate
review of the methods and data.
b. Declare lack of expertise to the editor for any included tech-
niques so that these can receive additional review.
3. Authors
a. Prior to experimentation, review relevant standards databases
and use the recommendations to guide the study design.
b. Consult experts in each of the required techniques.
c. Include as much experimental detail as possible in
manuscripts, making use of supplementary information.
Meanwhile, we  will just have to accept that many results
published over the last 20 years or so will not stand up to
detailed scrutiny and that it will take a while to improve the
consistency and reliability of the scientiﬁc literature archive.
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re accepted by the scientiﬁc community and that the con-
erns expressed in this editorial become redundant in the very
ear future. To assist this progression, we recommend that
uthors, reviewers and editors read the published proceed-
ngs of the symposium that analyses the challenges associated
ith tackling the reliability and reproducibility and of biomedi-
al research in the UK (http://www.acmedsci.ac.uk/policy/policy-
rojects/reproducibility-and-reliability-of-biomedical-research/).
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